title: Effects of lovastatin on cognitive function and psychological well-being.
abstract: OBJECTIVE
  Animal research and cross-sectional studies suggest that serum lipid concentrations may influence cognitive function, mood, and behavior, but few clinical trials have studied these effects.
  
  
  METHODS
  In this double-blind investigation, 209 generally healthy adults with a serum low-density-lipoprotein (LDL) cholesterol level of 160 mg/dL or higher were randomly assigned to 6-month treatment with lovastatin (20 mg) or placebo. Assessments of neuropsychological performance, depression, hostility, and quality of life were conducted at baseline and at the end of the treatment period. Summary effect sizes were estimated as z scores on a standard deviation (SD) scale.
  
  
  RESULTS
  Placebo-treated subjects improved between baseline and posttreatment periods on neuropsychological tests in all five performance domains, consistent with the effects of practice on test performance (all P <0.04), whereas those treated with lovastatin improved only on tests of memory recall (P = 0.03). Comparisons of the changes in performance between placebo- and lovastatin-treated subjects revealed small, but statistically significant, differences for tests of attention (z score = 0.18; 95% confidence interval (CI), 0.06 to 0.31; P = 0.005) and psychomotor speed (z score = 0.17; 95% CI, 0.05 to 0.28; P = 0. 004) that were consistent with greater improvement in the placebo group. Psychological well-being, as measured several ways, was not affected by lovastatin.
  
  
  CONCLUSIONS
  Treatment of hypercholesterolemia with lovastatin did not cause psychological distress or substantially alter cognitive function. Treatment did result in small performance decrements on neuropsychological tests of attention and psychomotor speed, the clinical importance of which is uncertain.
authors.affiliation: Center for Clinical Pharmacology (MFM), University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
authors.forename: M F
authors.initials: MF
authors.lastname: Muldoon
authors.forename: S D
authors.initials: SD
authors.lastname: Barger
authors.forename: C M
authors.initials: CM
authors.lastname: Ryan
authors.forename: J D
authors.initials: JD
authors.lastname: Flory
authors.forename: J P
authors.initials: JP
authors.lastname: Lehoczky
authors.forename: K A
authors.initials: KA
authors.lastname: Matthews
authors.forename: S B
authors.initials: SB
authors.lastname: Manuck
mesh_terms: D000328:Adult; D000339:Affect / Q000187:drug effects; D000786:Anger / Q000187:drug effects; D000924:Anticholesteremic Agents / Q000494:pharmacology*; D001288:Attention / Q000187:drug effects; D003071:Cognition / Q000187:drug effects*; D004311:Double-Blind Method; D005260:Female; D006791:Hostility; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy / Q000523:psychology*; D008055:Lipids / Q000097:blood; D008148:Lovastatin / Q000494:pharmacology*; D008297:Male; D008568:Memory / Q000187:drug effects; D008875:Middle Aged; D011597:Psychomotor Performance / Q000187:drug effects; D011788:Quality of Life; D013850:Thinking / Q000187:drug effects; D016896:Treatment Outcome
chemical_list: D000924:Anticholesteremic Agents; D008055:Lipids; D008148:Lovastatin